Precipio Inc. is a biotechnology company focused on developing innovative diagnostic tools for the early detection and diagnosis of cancer. Its primary function is to provide advanced oncology diagnostic services through technologies that aim to enhance the accuracy of cancer diagnoses. Precipio is known for its proprietary ICE COLD-PCR technology, which allows for the detection of low-frequency mutations efficiently, offering a cutting-edge approach in personalized medicine. The company's contributions are significant in the healthcare sector, impacting industries involved in oncology, clinical laboratories, and personalized therapy development. Headquartered in New Haven, Connecticut, Precipio serves clients that include hospitals, academic institutions, and the bio-pharmaceutical industry. By improving diagnostic processes, Precipio plays an essential role in advancing cancer research and patient treatment strategies globally, striving to improve patient outcomes through more accurate diagnostic methods.